Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharma Equity Group ASOCSE:PEG -1.39% 3-Year ROIIC % is 43.52 as of Dec. 2025, which is 100% above its 10-year median of 21.74. The stock has 3 warning signs investors should review. Among 1,322 Biotechnology companies, Pharma Equity Group AS ranks better than 70.95% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Pharma Equity Group AS's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 43.52%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Pharma Equity Group AS's 3-Year ROIIC % or its related term are showing as below:
OCSE:PEG's 3-Year ROIIC % is ranked better than 70.95% of 1322
companies
in the Biotechnology industry
Industry Median: -4.9
vs OCSE:PEG: 43.52
Pharma Equity Group AS (OCSE:PEG) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Pharma Equity Group AS 3-Year ROIIC % Related Terms
Pharma Equity Group AS 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Pharma Equity Group AS's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:PEG vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Pharma Equity Group AS's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Equity Group AS 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharma Equity Group AS's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Pharma Equity Group AS's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Pharma Equity Group AS (OCSE:PEG) has a 3-Year ROIIC % of 43.52 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Pharma Equity Group AS and its competitors. This is 100% above median its historical median of 21.74. According to the industry distribution chart, Pharma Equity Group AS ranks #384 out of 1322 companies in the Biotechnology industry, placing it in the top 29%.
Is Pharma Equity Group AS's 3-Year ROIIC % too high?
Pharma Equity Group AS's current 3-Year ROIIC % of 43.52 is 100% above median its 10-year median of 21.74. Based on the distribution chart, Pharma Equity Group AS ranks #384 out of 1322 companies in the Biotechnology industry, which is above the industry midpoint.
How does Pharma Equity Group AS's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharma Equity Group AS ranks #384 out of 1322 companies for 3-Year ROIIC %. This puts Pharma Equity Group AS in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Pharma Equity Group AS and its competitors. Pharma Equity Group AS's current 3-Year ROIIC % is 43.52, which is 100% above median its own 10-year median of 21.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Equity Group AS stock overvalued right now?
Pharma Equity Group AS (OCSE:PEG) has a current 3-Year ROIIC % of 43.52. The current 3-Year ROIIC % is 43.52, which is 100% above median its 10-year median of 21.74. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Pharma Equity Group AS (OCSE:PEG), the current 3-Year ROIIC % is 43.52 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pharma Equity Group AS is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develop technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement. Its drug candidates include RNX-011, RNX-021, RNX-022, RNX-023, RNX-041, and RNX-051 .
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:PEG has been successfully added to your 
